DiaMedica Therapeutics Income Statement (2017-2026) | DMAC

Income Statement Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
19.04M20.77M26.44M26.44M26.44M26.44M26.46M27.31M37.95M37.96M37.96M42.69M42.77M42.82M42.86M43.07M52.08M53.74M53.88M53.93M
Revenue & cost
Revenue (Quarter)
Operating items
Research & Development (Quarter)
2.33M1.87M1.97M1.96M1.64M2.27M3.62M2.54M3.27M3.68M3.68M3.93M4.98M6.47M5.66M5.82M6.44M6.70M7.99M8.15M
Selling, General & Administrative (Quarter)
1.08M1.38M1.56M1.41M1.49M1.70M1.90M2.20M1.89M2.17M2.06M1.71M1.90M1.95M2.49M2.19M2.60M2.51M2.50M2.35M
Operating Expenses (Quarter)
3.42M3.25M3.54M3.36M3.13M3.97M5.52M4.74M5.16M5.85M5.74M5.64M6.88M8.42M8.14M8.01M9.03M9.21M10.48M10.50M
Operating Income (Quarter)
-3.42M-3.25M-3.54M-3.36M-3.13M-3.97M-5.52M-4.74M-5.16M-5.85M-5.74M-5.64M-6.88M-8.42M-8.14M-8.01M-9.03M-9.21M-10.48M-10.50M
EBIT (Quarter)
-3.42M-3.25M-3.54M-3.36M-3.13M-3.97M-5.52M-4.74M-5.16M-5.85M-5.74M-5.64M-6.88M-8.42M-8.14M-8.01M-9.03M-9.21M-10.48M-10.50M
Non-operating items
Interest & Investment Income (Quarter)
-0.00M-0.05M-0.06M-0.06M0.01M0.09M0.04M-0.03M-0.06M2.00M-0.04M-0.01M0.13M2.23M-0.02M-0.02M0.44M-1.17M-0.08M-0.01M
Other Non Operating Income (Quarter)
-0.03M0.35M0.04M0.01M0.08M0.22M0.26M0.27M0.69M0.71M0.60M0.00M-0.00M0.02M0.44M0.00M-0.02M0.54M0.45M0.37M
Non Operating Income (Quarter)
-0.03M0.01M0.04M0.01M0.08M0.23M0.26M0.27M0.69M0.71M0.53M0.62M0.53M0.31M0.42M0.48M
Net income details
EBT (Quarter)
-3.44M-3.24M-3.50M-3.35M-3.05M-3.74M-5.26M-4.47M-4.46M-5.14M-5.14M-5.11M-6.27M-7.89M-7.70M-7.69M-8.61M-8.73M-10.04M-10.13M
Tax Provisions (Quarter)
0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.02M0.01M0.01M0.01M0.01M0.01M0.01M0.01M-4.93M0.01M0.01M
Profit After Tax (Quarter)
-3.45M-3.25M-3.51M-3.36M-3.05M-3.75M-5.27M-4.48M-4.54M-5.03M-5.15M-5.12M-6.14M-7.88M-7.71M-7.70M-8.56M-8.80M-10.04M-10.15M
Income from Continuing Operations (Quarter)
-3.45M-3.25M-3.51M-3.36M-3.06M-3.75M-5.27M-4.48M-4.47M-5.16M-5.15M-5.12M-6.27M-7.90M-7.71M-7.70M-8.62M-3.80M-10.04M-10.14M
Consolidated Net Income (Quarter)
-3.45M-3.25M-3.51M-3.36M-3.06M-3.75M-5.27M-4.48M-4.47M-5.16M-5.15M-5.12M-6.27M-7.90M-7.71M-7.70M-8.62M-3.80M-10.04M-10.14M
Income towards Parent Company (Quarter)
-3.45M-3.25M-3.51M-3.36M-3.06M-3.75M-5.27M-4.48M-4.47M-5.16M-5.15M-5.12M-6.27M-7.90M-7.71M-7.70M-8.62M-3.80M-10.04M-10.14M
Net Income towards Common Stockholders (Quarter)
-3.45M-3.25M-3.51M-3.36M-3.06M-3.75M-5.27M-4.48M-4.47M-5.16M-5.15M-5.12M-6.27M-7.90M-7.71M-7.70M-8.62M-3.80M-10.04M-10.14M
Additional items
EPS (Basic) (Quarter)
-0.18-0.16-0.13-0.13-0.12-0.14-0.20-0.16-0.12-0.16-0.14-0.13-0.15-0.20-0.18-0.18-0.17-0.08-0.19-0.19
Shares Outstanding (Quarter)
19.04M20.77M26.44M26.44M26.44M26.44M26.45M27.31M37.95M32.57M37.96M38.07M42.75M40.40M42.84M42.96M49.63M46.98M53.79M53.89M
EBITDA (Quarter)
-3.42M-3.25M-3.54M-3.36M-3.13M-3.97M-5.52M-4.74M-5.16M-5.85M-5.74M-5.64M-6.88M-8.42M-8.14M-8.01M-9.03M-9.21M-10.48M-10.50M
Interest Expenses (Quarter)
0.25M0.02M0.00M0.12M0.83M0.12M3.72M0.46M0.83M0.02M1.04M4.88M10.24M0.00M3.77M21.22M26.48M0.02M20.26M
Tax Rate (Quarter)
-0.20-0.22-0.20-0.21-0.23-0.19-0.13-0.16-0.16-0.43-0.14-0.14-0.11-0.11-0.08-0.08-0.0756.46-0.07-0.07